Background--Hydrogen sulfide (H 2 S) therapy is recognized as a modulator of vascular function during tissue ischemia with the notion of potential interactions of nitric oxide (NO) metabolism. However, little is known about specific biochemical mechanisms or the importance of H 2 S activation of NO metabolism during ischemic tissue vascular remodeling. The goal of this study was to determine the effect of H 2 S on NO metabolism during chronic tissue ischemia and subsequent effects on ischemic vascular remodeling responses.
H ydrogen sulfide (H 2 S) is a colorless, flammable, watersoluble gas with a pungent odor of rotten eggs, 1,2 which is produced from various sources in mammalian tissues, where it is generated during cysteine/homocysteine metabolism. 3 H 2 S is produced predominantly by tissuespecific enzymes, 4, 5 including cystathionine-b-synthase, cystathionine-c-lyase, and 3-mercaptosulfurtransferase. Similar to other gaseous mediators (eg, nitric oxide [NO] and carbon monoxide), H 2 S plays an important role in cardiovascular, neuronal, and endocrine systems, including ischemic and inflammatory processes. [6] [7] [8] [9] [10] H 2 S has been reported to be beneficial for cardiovascular dysfunctional states involving different responses. For example, H 2 S promotes vascular smooth muscle relaxation and induces vasodilation of isolated blood vessels by opening adenosine triphosphate-sensitive potassium (K-ATP) channel. 11 It has been reported that H 2 S potentiates antioxidant defenses via enhanced production of glutathione. 12 H 2 S also promotes tissue cytoprotection, as illustrated by inhibition of myocyte apoptosis during myocardial ischemia-reperfusion. 13 More recently, it has been proposed that H 2 S-NO interactions could occur, yet clear insight into this relationship is lacking. Conflicting reports have shown that H 2 S can (1) directly inhibit NO synthase (NOS) enzyme activity, (2) confer protection against experimental cardiac arrest in an endothelial NOS (eNOS)-dependent manner, (3) interact with NO to form unique reactive species involved in cardiovascular function, and (4) inhibit phosphodiesterase-5 activity potentiating NOS activity. [14] [15] [16] [17] [18] Unfortunately, no mechanistic information exists about how H 2 S affects NO metabolism and bioavailability during ischemic tissue vascular remodeling. Here, we identify novel H 2 S-NO crosstalk pathways, whereby H 2 S stimulates NOS expression as well as xanthine oxidoreductase (XO)-mediated nitrite anion reduction to NO, which subsequently regulates ischemic vascular remodeling responses. We also report measurement of therapeutic plasma and tissue free H 2 S levels and downstream molecular pathways that regulate these responses. These data demonstrate that H 2 S serves an important role in maintaining tissue NO bioavailability during chronic ischemia.
Methods

Chemicals and Reagents
General chemicals and tissue culture reagents were obtained from Sigma Chemicals. Anhydrous sodium sulfide was purchased from Alfa-Aesar Inc. Anti-Ki67 antibody was obtained from Abcam Inc (Cambridge, MA, USA). Anti-CD31 antibody was obtained from BD Biosciences (San Jose, CA, USA). Vectashield plus DAPI was obtained from Vector Laboratories. All secondary fluorophore-labeled antibodies were obtained from Jackson Immunoresearch Inc (West Grove, PA, USA). The murine MS-1 endothelial cell line was obtained from ATCC.
Animals and Experimental Procedures
Animals C57BL/6J, B6.129P2-Nos3 tm1Unc /J (eNOS-knockout) and Db/ Db diabetic male mice were purchased from Jackson Labs and used in this study. Mice were maintained at the Association for Assessment and Accreditation of Laboratory Animal Care International-accredited Louisiana State University Health Science Center-Shreveport animal resource facility and were maintained in accordance with the National Research Council's Guide for Care and Use of Laboratory Animals. All animal studies were approved by the institutional animal care and use committee (protocol P-08-041) and conformed to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health.
Mouse Hind-Limb Ischemia Model and Treatment Routes
Hind-limb ischemia was induced in 12-to 16-week-old C57Bl/ 6J wild-type and eNOS-knockout male mice and in 36-weekold Db/Db diabetic male mice, as we have reported previously. 19, 20 After anesthesia with ketamine/xylazine (100 mg/kg or 83 mg/kg) injection, ligation of the left femoral artery was performed. Mice were randomly assigned to different experimental groups by one investigator and were treated and evaluated by a second blinded investigator. Sodium sulfide with or without inhibitors was administered in the retro-orbital capillary plexus.
Laser Doppler Blood Flow Measurements
Laser Doppler blood flows were measured with a Vasamedics Laserflo BPM2 device in the gastrocnemius before ligation, after ligation, and at the indicated days after ligation, as we have reported previously.
19,20
Vascular Density and Cell Proliferation Measurements
Vascular density (anti-CD31) and cell proliferation (anti-Ki67) measurements were performed as we have reported previously. 19 Briefly, the gastrocnemius muscles from ischemic and nonischemic hind limbs were removed, dissected, and embedded in Optimal Cutting Temperature freezing medium and were stained with anti-CD31, anti-Ki67, and DAPI for immunofluorescent imaging. Simple PCI software version 6.0 (Compix Inc, Sewickly, PA) was used to quantitatively measure the surface area of CD31, Ki67, and DAPI staining.
Vascular Endothelial Growth Factor Enzyme-Linked Immunosorbent Assay
Ischemic and nonischemic tissue isolated from PBS control or H 2 S-treated wild-type/eNOS-knockout mice was harvested at various time points, and vascular endothelial growth factor (VEGF) expression was measured by enzyme-linked immunosorbent assay (ELISA) with the R&D VEGF Quantikine ELISA kit, as per the manufacturer's instructions.
Xanthine Oxidase Activity ELISA Assay
Ischemic and nonischemic tissue from control or H 2 S-treated mice was harvested at day 10. Xanthine oxidase activity was measured with an ELISA kit from Cayman Chemicals, as per the manufacturer's instructions.
Cyclic Guanosine Monophosphate ELISA Assay
Ischemic and nonischemic tissue from control or H 2 S-treated mice was harvested at day 10, and cyclic guanosine monophosphate (cGMP) level was measured with a cGMP assay from Sigma, as per the manufacturer's instructions.
Measurement of Plasma and Tissue Free H 2 S Levels
H 2 S was measured with monobromobimane (MBB) as we have reported. 21 Thirty microliters of plasma or tissue supernatant was reacted with 70 lL of Tris-HCl (100 mmol/L, pH 9.5, 0.1 mmol/L DTPA) and 50 lL of MBB solution (10 mmol/L) at 1% oxygen in a hypoxic chamber at room temperature. Sulfidedibimane (SDB) reaction product was analyzed with a Shimadzu Prominence Ultra Fast high-performance liquid chromatography system. Specimen concentration was calculated by comparison to SDB sulfide standards.
Measurement of NO Generation
A Sievers 280i NO analyzer was used to measure H 2 Smediated NO production as we have reported. 19 Figure 1A) . Conversely, 0.1 mg/kg (2.6 lmol/ kg per day) did not significantly alter ischemic hind-limb blood flow compared to PBS control. Thus, the therapeutic dose of 0.5 mg/kg was used for the rest of the study. Figure 1B illustrates the pharmacokinetic profile of plasma H 2 S levels after a single injection of 0.5 mg/kg sodium sulfide, revealing a quick rise of plasma H 2 S levels to %32 lmol/L within 1 minute of injection, which falls rapidly back to baseline levels (%600 nmol/L) within 30 minutes. We next examined steady-state plasma free H 2 S levels taken 2 hours after the first morning dose of 0.5 mg/kg sodium sulfide, as shown in Figure 1C . Steady-state free plasma H 2 S is elevated within 1 day of beginning therapy and then decreases between days 3 and 7 and returns to baseline levels by day 10. We next measured tissue free H 2 S levels at days 3 and 7 in nonischemic and ischemic tissues from sodium sulfide-and PBS-treated mice. Ischemic tissue H 2 S levels from sodium sulfide-treated animals were elevated significantly above those of PBS-treated controls at day 3 ( Figure 1D ). Importantly, tissue H 2 S levels were increased only in ischemic tissues, which suggests preferential bioavailability of H 2 S in ischemic tissue. Figure 1E shows that by day 7, tissue H 2 S levels had returned to baseline. Figure 2A through 2D show the representative photomicrographs of angiogenic index in nonischemic and ischemic tissues with or without H 2 S treatment. Figure 2E and 2F represent the H 2 S dose-dependent stimulation of ischemic tissue angiogenesis (CD31/DAPI) and cell proliferation activity (Ki67/DAPI), respectively. These data reveal that H 2 S plays major role in restoration of ischemic hindlimb blood flow or ischemic vascular remodeling and also indicate rapid and selective augmentation of free H 2 S bioavailability during chronic tissue ischemia.
H 2 S Restores Ischemic Tissue Blood Flow in a NO-Dependent Manner
Previous reports suggested that H 2 S confers cardioprotective effects involving NO metabolism. 15, 17 Therefore, we administered an NO scavenger, cPTIO (1 mg/kg), to determine whether NO is involved in mediating ischemic tissue reperfusion during H 2 S therapy. Figure 3A shows that cPTIO significantly blunts the effects of H 2 S therapy on ischemic tissue blood flow in wild-type mice, demonstrating a key role for NO. Next, experiments were performed with eNOSknockout mice to determine whether H 2 S therapy mediates its effects on NO metabolism through this enzyme. Figure 3B shows that H 2 S therapy significantly restored ischemic hindlimb blood flow in eNOS À/À mice to 75% of preligation levels compared to PBS therapy. blood flow by using the NOS blocker L-NAME (5 mg/kg). L-NAME did not affect H 2 S-dependent restoration of eNOSdeficient ischemic hind-limb reperfusion, suggesting that other NOS activity is not involved in this response ( Figure 3C ). Experiments were then performed in eNOS À/À animals with cPTIO plus H 2 S, which completely abrogated H 2 S-mediated increased ischemic hind-limb blood flow ( Figure 3D ). cPTIO completely blocks H 2 S-mediated angiogenesis and cell proliferation responses in ischemic tissues in wild-type animals ( Figure 4A and 4B, respectively). Importantly, Figure 4C and 4D show that cPTIO but not L-NAME significantly prevents H 2 S-mediated increases in the CD31:DAPI and Ki67:DAPI ratios of ischemic tissue in eNOS À/À animals, confirming the importance of alternative NO generation for H 2 S-mediated ischemic angiogenesis.
Increased NO Production and cGMP Expression by H 2 S Therapy in Ischemic Tissue
Experiments then were performed to measure NO metabolites in plasma and tissue during H 2 S therapy. Figure 5A shows that H 2 S increases plasma nitrite levels at day 3 in wild-type mice and further increases plasma nitrite, nitrosothiol, and NO-heme levels by day 10 of therapy.
Figure 5B reveals that total NOx levels (a combination of nitrite, nitrosothiol, and nitrosoheme) were selectively and significantly increased in ischemic tissues from wild-type mice at day 10 alone. Similar NO metabolite measurements were performed in eNOS À/À mice, with Figure 5C illustrating that H 2 S therapy did not significantly increase plasma NO metabolites at either time point. Interestingly, tissue total NOx levels were also selectively increased by H 2 S therapy in ischemic tissues from eNOS À/À mice ( Figure 5D ), although tissue NOx levels in eNOS À/À mice were smaller than those of wild-type mice. These findings were confirmed independently with cGMP ELISA, which is indicative of NO generation. Figure 5E shows that H 2 S therapy selectively increases ischemic tissue cGMP production in both wildtype and eNOS À/À mice. Figure 6 reports Western blot analysis of NOS total protein expression and eNOS phosphorylation at different times in tissues from wild-type and eNOS À/À mice. These blots reveal that total eNOS expression and phosphorylation was increased at day 3 but not at day 10 in wild-type mice. Moreover, an increase in total iNOS expression was observed in ischemic tissues at day 3 and decreased by day 10 in both mouse genotypes, whereas nNOS expression was moderately increased in nonischemic and ischemic tissue from wild-type and eNOS À/À mice. Together, Western blot data, NO metabolite measurements, and ischemic limb blood flow data implicate a role for NOS activity during H 2 S therapy; however, NOS blockade in eNOS À/À mice did not attenuate the effects of H 2 S on ischemic vascular remodeling, suggesting other mechanisms of NO production.
H 2 S Stimulates Nitrite Reduction to NO Under Hypoxia
We next examined whether H 2 S could increase NO bioavailability through NOS-independent mechanisms. Endothelial cells were subjected to normoxic or hypoxic conditions, placed into a NO-chemiluminescent reaction vessel, and Figure 5 . H 2 S effects on plasma and tissue NO formation and bioavailability. A and B, H 2 S-induced plasma and tissue NOx levels, respectively, in wild-type mice at day 3 and day 10 after ligation. C and D, H 2 S-mediated NOx levels in plasma and ischemic tissues of eNOS À/À mice at day 3 and day 10 after ligation. E, H 2 S-mediated cGMP levels in ischemic and nonischemic tissues from wild-type and eNOS À/À mice at day 10 after ligation. RSNO indicates nitrosothiol; WT, wild type; KO, knockout; and Isch, ischemic. n=5 animals per cohort. *P<0.05, **P<0.001 compared to PBS control data, #P<0.05 compared to eNOS À/À PBS ischemic tissue data. Figure 6 . Western blot analyses of NOS isoforms in wild-type and eNOS À/À mice. Western blots and corresponding quantification below comparing levels of phospho-eNOS (Ser 1177), total eNOS, iNOS, and nNOS, respectively, from the nonligated (NI) and ligated (I) gastrocnemius muscle tissues of wild-type mice (A to D) and eNOS À/À mice (E to G), respectively. n=5 animals per genotype per time point, *P<0.05 or *P<0.001 as compared to nonligated tissues. Western blots were repeated 3 times. treated with sodium sulfide to examine NO production. Figure 7A shows the release of NO after administration of 50 lmol/L sodium sulfide to either hypoxic or normoxic endothelial cells. H 2 S significantly increased NO release from hypoxic but not normoxic cultured endothelium over a 1-minute period. Studies were then performed to confirm that the H 2 S-dependent chemiluminescent peak from hypoxic endothelium was indeed NO. Figure 7B shows that the NO scavenger cPTIO (200 lmol/L) significantly blunted H 2 Smediated NO formation. Moreover, protein fixation with 3% paraformaldehyde treatment of hypoxic endothelial cells also prevented H 2 S-dependent NO formation, indicating that H 2 Smediated NO production involves protein function. Figure 7C further demonstrates that H 2 S-mediated NO formation is nitrite dependent, because sulfanilamide (1 mmol/L) treatment of hypoxic endothelial cells completely prevented NO formation. Treatment with febuxostat (10 nmol/L), a XO inhibitor, blocked H 2 S-mediated NO formation, implicating XO-mediated nitrite reduction to NO. Figure 7D reports quantitative measurement of NO formation from dose-dependent treatment (25 to 100 lmol/L) of H 2 S on hypoxic versus normoxic endothelial cells coupled with various inhibitors of specific molecular targets. Importantly, inhibition of protein thiol modification with NEM, XO with febuxostat, nitrite availability with sulfanilamide, NO bioavailability with cPTIO, or protein fixation with paraformaldehyde all significantly blocked NO production at a range of H 2 S concentrations. In contrast, L-NAME treatment did not significantly block H 2 Smediated NO formation.
To confirm that H 2 S augments XO-mediated nitrite reduction to NO, we performed recombinant XO protein experiments in conjunction with NO-chemiluminescent analysis. Figure 7E shows NO-chemiluminescent traces from the addition of different concentrations of recombinant XO protein to a solution of 50 lmol/L nitrite anion, followed by administration of 50 lmol/L sodium sulfide. Resulting traces reveal a slight increase in NO production upon addition of the highest XO concentration (0.01 U) (as expected) that is followed by a significant spike in NO formation upon addition of sulfide. Figure 7F reports the amounts of NO generation upon addition of 50 lmol/L sodium sulfide to different XO concentrations in the presence of nitrite. Sulfide robustly catalyzes the reaction of 0.01 U of XO to generate %300 nmol/L NO from nitrite reduction. Importantly, equimolar (50 lmol/L) addition of sodium sulfide to sodium nitrite in Hank's balanced salt solution alone did not increase NO formation ( Figure 7G ). Figure 8 reports the effects of H 2 S on phospho-eNOS and total eNOS as well as iNOS and nNOS expression in normoxic versus hypoxic endothelial cells. PBS or 50 lmol/L sodium sulfide was added to the cells, which were incubated for 5, 15, 30, and 60 minutes. H 2 S significantly increased phosphoeNOS levels by 60 minutes, which is consistent with findings from Yusof et al ( Figure 8A) . 22 However, H 2 S did not significantly alter eNOS phosphorylation under hypoxic conditions at any time point examined ( Figure 8B ). Moreover, H 2 S stimulated moderate (%50%) differences in iNOS expression under normoxic conditions that was not observed under hypoxia ( Figure 8C and 8D). Changes in nNOS expression were decreased by H 2 S stimulation under both normoxic and hypoxic conditions ( Figure 8E and 8F). Finally, endothelial XO expression and activity was increased under hypoxic conditions, confirming the availability of this key enzyme for H 2 S-mediated nitrite reduction to NO ( Figure 8G ). Together, these data clearly demonstrate that H 2 S quickly augments NO formation in hypoxic endothelial cells within minutes after its addition in a XO-dependent manner and that H 2 S does not significantly increase eNOS expression under hypoxic conditions.
Increased Xanthine Oxidase Activity Is Required for H 2 S-Dependent Restoration of Blood Flow in Hind-Limb Ischemia
Having observed that sulfide can increase XO nitrite reductase activity under hypoxic conditions, we examined whether H 2 S therapy altered XO activity in vivo and whether XO activity was important for H 2 S-mediated ischemic limb reperfusion. Figure 9A and 9B show that XO activity was significantly increased in H 2 S-treated ischemic tissues of wild-type and eNOS-knockout mice. Treatment with the XO inhibitor febuxostat (5 mg/kg twice a day) blocked H 2 Smediated increases in ischemic tissue XO activity, as well as H 2 S-mediated restoration of ischemic hind-limb blood flow, in both wild-type and eNOS À/À mice ( Figure 9C and 9D) .
Moreover, febuxostat also blunted H 2 S-mediated increases in angiogenic activity in wild-type and eNOS À/À mice ( Figure 9E and 9F), demonstrating that XO is required to stimulate the H 2 S-mediated ischemic angiogenesis.
H 2 S Increases Ischemic Tissue Hypoxia-Inducible Factor-1a VEGF Levels in a NO-Dependent Manner
NO and hypoxia-inducible factor (HIF)-1a are known to enhance VEGF expression during tissue ischemia. 23, 24 We next examined downstream molecular mechanisms of H 2 S treatment on endothelial cell HIF-1a activation in an oxygendependent manner. H 2 S treatment of normoxic endothelial cells did not alter HIF-1a activity over a 12-hour time period ( Figure 10A ). However, 50 lmol/L H 2 S stimulated a 5-fold increase in HIF-1a activation under hypoxic conditions ( Figure 10B ). HIF-1a activation plays an important role in regulating hypoxic endothelial cell proliferation responses and has been shown to be activated by NO. 25, 26 We found that H 2 S stimulated a moderate increase in endothelial cell proliferation at 21% O 2 ( Figure 10C ) but that H 2 S elicited a robust 7-fold increase in endothelial cell proliferation under hypoxia (1% O 2 ) that was significantly inhibited by HIF-1a small interfering RNA or cPTIO. Moreover, we found that H 2 S therapy significantly increased HIF-1a expression in ischemic tissues, which was completely attenuated by XO inhibition with febuxostat ( Figure 10D and 11) . Together, these data demonstrate that H 2 S increases HIF-1a expression and function under low-oxygen conditions that involve XO activity and NO formation. Next, we examined whether H 2 S augments ischemic tissue angiogenesis and reperfusion involving VEGF production. Figure 12A shows gastrocnemius tissue VEGF levels at day 7 in either PBS-treated or 0.5 mg/kg H 2 S-treated animals. H 2 S significantly augmented ischemic tissue VEGF levels over that of PBS treatment, as measured by ELISA. H 2 S further increased ischemic tissue levels of VEGF over that of PBS treatment at day 10 ( Figure 12B ). Importantly, combined treatment of H 2 S plus cPTIO significantly blocked H 2 S induction of VEGF during tissue ischemia, indicating that NO is crucially important for H 2 S augmentation of VEGF during ischemia ( Figure 12C ). We also discovered that H 2 S could increase ischemic tissue VEGF expression in eNOS-deficient mice, which was blocked by cPTIO but not L-NAME ( Figure 12D ). These data reinforce the importance of H 2 S-dependent nitrite reduction to NO as a key regulator of ischemic tissue VEGF induction. Lastly, we found that scavenging VEGF with the VEGF 164 aptamer (Macugen) (50 mg/kg) could significantly prevent H 2 S-mediated ischemic limb reperfusion in wild-type animals ( Figure 12E ). VEGF 164 aptamer also significantly blunted H 2 S-mediated VEGF bioavailability in ischemic tissues ( Figure 12F ). Heat-denatured VEGF 164 aptamer (D-VEGF aptamer) control treatments were unable to block H 2 S-mediated ischemic limb reperfusion or VEGF expression, revealing that H 2 S selectively stimulates VEGF expression in ischemic tissues in a NO-dependent manner.
H 2 S Increases Diabetic Ischemic Hind-Limb Reperfusion and Angiogenesis in a VEGFDependent Manner
Impaired ischemic vascular remodeling during diabetes in Db/ Db mice involves defective VEGF expression and signaling, 27 with aged diabetic Db/Db mice manifesting severe defects in ischemic angiogenic responses. 28, 29 We next examined whether exogenous H 2 S therapy could augment ischemic limb reperfusion and vascular growth in 9-month-old, aged Db/Db mice subjected to femoral artery ligation. To emulate therapeutic situations, we delayed H 2 S administration until day 5 after ligation, as we have recently reported, thus allowing the establishment of tissue ischemia. 30 Figure 13A incorporation after H 2 S dose-dependent treatment in normoxic (21% O 2 ) conditions. B, Endothelial BrdU incorporation after H 2 S dose-dependent treatment in hypoxic (1% O 2 ) conditions. C, Effect of 50 lmol/L sodium sulfide on HIF-1a activity under normoxic (21% O 2 ) conditions. D, Effect of sodium sulfide on HIF-1a activity under hypoxic (1% O 2 ) conditions in vitro. E, Effect of NEM, cPTIO, or HIF-1a small interfering RNA (siRNA) knockdown on H 2 S-mediated hypoxic endothelial cell proliferation. n=6 replicates performed in triplicate, *P<0.05 compared to PBS, #P<0.05 compared to H 2 S or diethylamine NONOate (DEANO) treatment alone. Figure 11 . H 2 S increases HIF-1a expression in ischemic tissues in an XO-dependent manner. Tissues were stained with anti-CD31 (red), anti-HIF-1a (green), and DAPI nuclear counterstain (blue). A, CD31 and HIF-1a staining in PBS-treated ischemic tissue at day 10. B, CD31 and HIF-1a staining in H 2 S-treated ischemic tissue at day 10. C, CD31 and HIF-1a staining in PBS+febuxostat treatment. D, CD31a and HIF-1α staining in H 2 S+febuxostat treatments. and 13B illustrate that delayed H 2 S therapy significantly restored ischemic hind-limb perfusion and capillary-to-myofiber ratios compared to PBS control treatment. Figure 13C and 13D illustrate that cotreatment with H 2 S plus a VEGF 164 -inhibiting aptamer significantly prevented H 2 S-mediated ischemic limb reperfusion and increased ischemic tissue VEGF protein levels compared to denatured VEGF 164 control aptamer treatment. Finally, Figure 13E and 13F clearly demonstrate that H 2 S plus VEGF 164 aptamer treatment significantly prevented increased ischemic vascular density and proliferation. Together, these data highlight the potent therapeutic effect of H 2 S on diabetic ischemic vascular remodeling and tissue reperfusion, which depends on increased VEGF expression and angiogenic activity.
Discussion
H 2 S-NO pathway interactions have been suggested, although specific mechanistic information on how these gasotransmitters influence one another remains poorly understood. Our findings provide significant insight into how H 2 S affects NO metabolism responses during ischemic vascular remodeling such that (1) H 2 S therapy restores ischemic hind-limb blood flow in a NO-dependent manner, (2) H 2 S increases NOS expression concomitant with stimulating XO-mediated nitrite reduction to NO in ischemic tissues, and (3) H 2 S stimulates the ischemic vascular growth by augmenting the expression and activity of HIF-1a and VEGF in a NO-dependent manner. We also clearly observed that H 2 S selectively accumulates in and significantly increases NO bioavailability of chronically ischemic tissue. These beneficial effects of H 2 S on ischemic tissue NO levels do not critically depend on NOS activity but do significantly depend on nitrite anion reduction back to NO. These findings further define biochemical mechanisms in which H 2 S increases tissue NO bioavailability that occurs during cardiovascular disease and tissue ischemia.
Exogenous H 2 S has been reported to interfere with NO donor vasodilation responses, presumably through direct interactions generating unknown species. 16 However, the biological effect of H 2 S seems to be oxygen dependent, as it mediates aortic ring vasoconstriction at high oxygen tensions but vasodilation at low oxygen tension. 31 Here, we found that H 2 S treatment increased ischemic vascular remodeling, consistent with previous studies; however, our results identified H 2 S-dependent release of NO through nitrite reduction as a key cytoprotective mechanism during tissue ischemia. that eNOS expression or function is not essential for H 2 Smediated ischemic vascular remodeling or NO formation, revealing that H 2 S stimulation of XO-dependent nitrite reduction to NO acts as an alternative mechanism to maintain NO bioavailability. Our findings are consistent with classical studies from the Massey laboratory that demonstrated the importance of hydropersulfide formation at the active site of XO in regulating its activity, such that sodium sulfide was shown to increase XO protein activity, which we confirmed in vivo and in vitro. 36, 37 We and others have reported that nitrite anion reduction to NO mediates cytoprotection during acute ischemia-reperfusion injury and chronic tissue ischemia. 19, 38 We previously have reported that nitrite-dependent NO formation rapidly Figure 13 . H 2 S restores established diabetic ischemic limb reperfusion and angiogenic activity in a VEGF-dependent manner. A, Ischemic hindlimb blood flow changes in 9-month-old diabetic mice subjected to femoral artery ligation followed by delayed 0. augments ischemic hind-limb reperfusion and ischemic vascular remodeling. 19 The biological potency of H 2 S treatment for chronic tissue ischemia is similar to that of sodium nitrite, which suggests that a major pathway of the beneficial effects of H 2 S might occur via nitrite-dependent NO formation apart from other previously defined effects, such as antioxidant, signaling (K-ATP or phosphodiesterase 5), and transcription factor changes. Figure 14 supports this hypothesis, because blockade of K-ATP channels (known to be activated by H 2 S) with glibenclamide does not prevent H 2 S-increased ischemic hind-limb blood flow or ischemic vascular remodeling. Taken together, it appears that XO-mediated nitrite reduction to NO plays a key role in mediating the beneficial effects of H 2 S for ischemic vascular remodeling. NO formation through XO-mediated nitrite reduction critically serves to maintain NO bioavailability in addition to NOS-dependent mechanisms. 39 Thus, XO is an important source for NOS-independent NO generation under conditions in which NOS activity could be limiting, and our findings clearly show that sulfide can stimulate recombinant XOdependent nitrite reduction to NO. This most likely occurs through posttranslational modification of XO (presumably sulfhydration) that is currently being studied in greater detail. Nonetheless, in vitro and in vivo XO-inhibition studies revealed XO activation to be a dominant mediator of ischemic tissue NO formation because febuxostat, but not L-NAME inhibition of NOS activity, completely prevented the beneficial effects of H 2 S in eNOS À/À mice. This is confirmed by the observation that XO-mediated H 2 S-induced NO production can enhance cGMP production in ischemic tissue of eNOS À/À and wildtype mice. Future studies will further examine how H 2 S affects XO activity in vivo and in vitro regulating NO production and bioavailability. Recent reports suggest that H 2 S could positively regulate HIF-1a activity. 40, 41 These studies showed that H 2 S-enhanced hypoxia induced HIF-1a and VEGF expression in vascular smooth muscle cells, which enhanced endothelial cell viability. Our findings further advance our understanding of H 2 S and HIF-1a because H 2 S stimulation of endothelial cell proliferation was maximal under hypoxia that critically required NO-dependent HIF-1a activity. Endogenous NO is known to stimulate VEGF synthesis and VEGF-induced angiogenesis that is blunted by NOS inhibition. [42] [43] [44] Likewise, angiogenesis is impaired when NO bioavailability is attenuated, as seen during hind-limb ischemia in eNOS-knockout mice that is not significantly reversed by administration of VEGF. 45 Moreover, NO along with cGMP production exerts these effects by increasing expression of VEGF. 42, 46, 47 Our results are in agreement with these previous reports and reveal that H 2 S increases VEGF expression in eNOS
ischemic tissues in a NO-dependent manner that can stimulate angiogenesis in ischemic tissues. The implications of our results are striking, as ischemic VEGF induction in eNOS À/À mice is ultimately NO dependent, which reinforces the importance of crosstalk between H 2 S and NO metabolism pathways.
In conclusion, we have discovered that H 2 S selectively augments NO production and associated downstream vascular growth and remodeling in chronically ischemic tissues by influencing NOS expression and critically stimulating nitrite reduction to NO via XO. H 2 S has been proposed to be a novel therapeutic for ischemia-reperfusion injury; however, our data also demonstrate its benefit for NO-dependent ischemic vascular disorders that have yet to achieve broad clinical resolution. 48 Further studies are needed to better understand the biological and therapeutic implications of H 2 S-dependent nitrite reduction to NO, including downstream signaling pathways that are activated to confer ischemic tissue cytoprotection. 
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